Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
July 25 2024 - 4:00PM
Business Wire
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it
will host its second quarter 2024 investor update conference call
and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024.
Individuals interested in participating in the call should dial
(888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international)
using conference ID number and event passcode 2530602. To access
the webcast, please visit the Investors section of Ironwood’s
website at www.ironwoodpharma.com.
The call will be available for replay via telephone starting
Thursday, August 8, 2024 at approximately 11:30 a.m. Eastern Time,
running through 11:59 p.m. Eastern Time on Thursday, August 22,
2024. To listen to the replay, dial (800) 770-2030 (U.S. and
Canada) or (609) 800-9909 (international) using conference ID
number 2530602. The archived webcast will be available on
Ironwood’s website for 1 year beginning approximately one hour
after the call has completed.
About Ironwood Pharmaceuticals Ironwood Pharmaceuticals
(Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading
gastrointestinal (GI) healthcare company on a mission to advance
the treatment of GI diseases and redefine the standard of care for
GI patients. We are pioneers in the development of LINZESS®
(linaclotide), the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC). LINZESS is also approved for
the treatment of functional constipation in pediatric patients ages
6-17 years-old. Ironwood is also advancing apraglutide, a
next-generation, long-acting synthetic GLP-2 analog being developed
for rare gastrointestinal diseases, including short bowel syndrome
with intestinal failure (SBS-IF), as well as several earlier stage
assets. Building upon our history of GI innovation, we keep
patients at the heart of our R&D and commercialization efforts
to reduce the burden of GI diseases and address significant unmet
needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in
Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors
on our website at www.ironwoodpharma.com. In addition, follow us on
Twitter and on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725809167/en/
Investors: Greg Martini, 617-374-5230
gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395 mroache@ironwoodpharma.com
Media: Beth Calitri, 978-417-2031
bcalitri@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Aug 2023 to Aug 2024